Myovant Sciences Total Assets 2017-2022 | MYOV

Myovant Sciences total assets from 2017 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Myovant Sciences Annual Total Assets
(Millions of US $)
2022 $520
2021 $725
2020 $106
2019 $173
2018 $119
2017 $185
2016 $0
Myovant Sciences Quarterly Total Assets
(Millions of US $)
2022-12-31 $404
2022-09-30 $484
2022-06-30 $460
2022-03-31 $520
2021-12-31 $604
2021-09-30 $680
2021-06-30 $728
2021-03-31 $725
2020-12-31 $774
2020-09-30 $136
2020-06-30 $127
2020-03-31 $106
2019-12-31 $130
2019-09-30 $184
2019-06-30 $251
2019-03-31 $173
2018-12-31 $202
2018-09-30 $168
2018-06-30 $154
2018-03-31 $119
2017-12-31 $138
2017-09-30 $136
2017-06-30 $163
2017-03-31 $185
2016-12-31 $194
2016-09-30 $2
2016-06-30 $1
2016-03-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.615B $0.231B
Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders, including advanced prostate cancer. The company's product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.721B 9.45
GSK (GSK) United Kingdom $71.915B 9.49
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.215B 19.14
Ginkgo Bioworks Holdings (DNA) United States $4.249B 0.00
Arcus Biosciences (RCUS) United States $1.532B 23.00
Biohaven (BHVN) United States $1.307B 0.00
Emergent Biosolutions (EBS) United States $0.726B 5.71
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Ambrx Biopharma (AMAM) United States $0.071B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.023B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00